Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD63m

    Last close

    USD0.68

    ▲ 0.10 (16.35%)

    Creotech Instruments

    MCap

    PLN346m

    Last close

    PLN174.00

    ▲ 23.50 (15.61%)

    Creo Medical

    MCap

    GBP80m

    Last close

    GBP0.19

    ▲ 2.25 (13.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – Futura Medical

Executive Interview – Futura Medical

The next 12 months should mark the defining events in Futura Medical’s journey towards sustainable profitability. Futura Medical operates with a low fixed-cost base, seeking to outsource most major operations (such as conducting clinical trials, preparing regulatory submissions, formulation and stability testing) and using specialist contractors as appropriate. This ‘virtual’ approach is particularly suitable for a small development player, allowing spending to be tightly controlled with cash outflows occurring only when really needed. With a cash burn of around £2m pa, Futura Medical should be funded through to profitability. The recent £14m placing allows a material acceleration of new product development, notably the pain relief gel portfolio.

< Previous
Next >

You may also be interested in these:

Investment Companies

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

TMT

IP Group – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free